Medical Centre of Childhood and Adolescence, Frankfurt, Germany.
Horm Res Paediatr. 2013;80(1):1-5. doi: 10.1159/000351800. Epub 2013 Jul 11.
BACKGROUND/AIMS: Treatment of children with growth disorders with recombinant human growth hormone is necessary for improved outcomes, including final height.
Adherence data from the Observational Study Saizen®-online, recorded with the easypod™ device collected between October 2009 and May 2011, were analyzed in pediatric patients receiving recombinant human growth hormone treatment for a variety of growth disorders.
Data from 75 children (46 boys, 29 girls) with different growth disorders were analyzed over a period of 343 ± 201 (SD) days. Boys and girls showed similar mean ± SD adherence rates of 90.5 ± 3.1% and 92.2 ± 10.7%, respectively. Pubertal children (n = 41) had a significantly lower adherence rate (89.1 ± 13.7%) than prepubertal children (n = 29) (96.5 ± 3.9%; p < 0.005). There were nonsignificant differences in adherence rates according to diagnosis: growth hormone deficiency (n = 48) 91.4 ± 11.0%, small for gestational age (n = 18) 91.1 ± 15.3%, Turner syndrome (n = 6) 86.0 ± 14.5%, and chronic renal failure (n = 3) 99.3 ± 1.0%, although the latter two groups were small.
Our data indicate that only a small number of pediatric patients using the easypod device had poor adherence to treatment. Further reliable adherence data are required to identify factors affecting long-term adherence in this population.
背景/目的：为了改善治疗效果，包括最终身高，生长障碍儿童需要接受重组人生长激素治疗。
对 2009 年 10 月至 2011 年 5 月期间使用 easypod 设备记录的 Observational Study Saizen®-online 中的依从性数据进行分析，该研究纳入了接受重组人生长激素治疗各种生长障碍的儿科患者。
共分析了 75 名患有不同生长障碍的儿童（46 名男孩，29 名女孩）的数据，这些儿童的治疗时间为 343±201（SD）天。男孩和女孩的平均依从率分别为 90.5±3.1%和 92.2±10.7%，显示出相似的趋势。青春期儿童（n=41）的依从率明显低于青春期前儿童（n=29）（89.1±13.7% vs 96.5±3.9%；p<0.005）。根据诊断，依从率没有显著差异：生长激素缺乏症（n=48）91.4±11.0%、小于胎龄儿（n=18）91.1±15.3%、特纳综合征（n=6）86.0±14.5%和慢性肾衰竭（n=3）99.3±1.0%，尽管后两组的例数较少。
我们的数据表明，只有少数使用 easypod 设备的儿科患者治疗依从性较差。需要进一步获得可靠的依从性数据，以确定影响该人群长期依从性的因素。
